On January 15, 2025, the Department of Health and Human Services (HHS) and Drug Enforcement Administration (DEA) published a rule related to telemedicine prescribing of controlled substances, including a proposed rule on special registrations for  telemedicine. The proposed rule outlines three types of registration to waive in-person visit requirements prior to virtual prescribing of controlled substances. The rule also proposes a state registration for every state in which a patient is treated by the special registrant. Providers would need to apply for the special registrations. Finally, the DEA also proposes that providers be required to review nationwide prescription drug monitoring programs after three years. LeadingAge advocated multiple times for flexibility in this COVID-era rule, due to the emergent nature of hospice, palliative care, and home health prescribing needs. We will provide a more in-depth review of the rule soon. Comments on the proposed rule are due March 15.